Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial
Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial
复制标题
DOI：
10.1002/hep.30690
复制
发表时间：
2019-11-01
期刊：
影响因子：
13.5
通讯作者：
Gillevet, Patrick M.
中科院分区：
文献类型：
--
作者：
Bajaj, Jasmohan S.;Salzman, Nita H.;Gillevet, Patrick M.
尽管采用了标准治疗（SOC;利福昔明/乳果糖），但肝性脑病（HE）仍可能导致严重发病。粪便微生物移植（FMT）灌肠抗生素后是安全的，但FMT的影响，没有抗生素使用胶囊路线需要调查。这项工作的目的是在弗吉尼亚州的一项随机、单盲、安慰剂对照临床试验中确定囊袋FMT后HE的安全性、耐受性和对粘膜/粪便微生物群和脑功能的影响。MELD（终末期肝病模型）的肝硬化复发性HE患者
Hepatic encephalopathy (HE) can cause major morbidity despite standard of care (SOC; rifaximin/lactulose). Fecal microbial transplant (FMT) enemas postantibiotics are safe, but the effect of FMT without antibiotics using the capsular route requires investigation. The aim of this work was to determine the safety, tolerability, and impact on mucosal/stool microbiota and brain function in HE after capsular FMT in a randomized, single-blind, placebo-controlled clinical trial in Virginia. Patients with cirrhosis with recurrent HE with MELD (Model for End-Stage Liver Disease)